Format

Send to

Choose Destination
Clin Lung Cancer. 2009 Sep;10(5):371-4. doi: 10.3816/CLC.2009.n.052.

MAGRIT: the largest-ever phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy.

Author information

1
GlaxoSmithKline Oncology, Collegeville, PA 19426, USA. preeta.3.tyagi@gsk.com

Abstract

This clinical trial summary provides the background and rationale for a randomized trial, MAGRIT, to investigate the efficacy of MAGE-A3 antigen-specific cancer immunotherapeutic (ASCI) agents in preventing cancer relapse, when administered after tumor resection, in patients with MAGE-A3-positive stages IB, II, and IIIA non-small-cell lung cancer. The study will also evaluate potential side effects of MAGE-A3 ASCIs. The primary endpoint is disease-free survival. The secondary endpoint is prospective validation of the gene signature predictive of benefit from MAGE-A3 ASCI therapy.

PMID:
19808198
DOI:
10.3816/CLC.2009.n.052
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center